DxS this week launched its B-RAF Mutation Detection Kit, which detects V600E, the most common mutation in the B-RAF oncogene. The V600E occurs in many types of cancer, including melanoma, colorectal, and lung cancer.
“Tumors with the V600E mutation are exquisitely sensitive to drugs that inhibit the MEK pathway; therefore, this assay is likely to be useful to investigate which patients will respond to these drugs,” DxS said in a statement. Pfizer, AstraZeneca, and Roche are some companies currently developing MEK inhibitor drugs.
According to DxS, the assay can detect less than 1 percent of mutants in a background of wild type genomic DNA and has a limit of detection of 5 copies or below.